A068760 Stock Overview
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea.
Celltrion Pharm Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||₩77,600.00|
|52 Week High||₩174,466.02|
|52 Week Low||₩72,300.00|
|1 Month Change||-11.42%|
|3 Month Change||-10.18%|
|1 Year Change||-40.44%|
|3 Year Change||70.19%|
|5 Year Change||347.77%|
|Change since IPO||512.05%|
Recent News & Updates
Does Celltrion Pharm (KOSDAQ:068760) Deserve A Spot On Your Watchlist?
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
Do Institutions Own Celltrion Pharm, Inc. (KOSDAQ:068760) Shares?
If you want to know who really controls Celltrion Pharm, Inc. ( KOSDAQ:068760 ), then you'll have to look at the makeup...
These 4 Measures Indicate That Celltrion Pharm (KOSDAQ:068760) Is Using Debt Reasonably Well
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Do Celltrion Pharm's (KOSDAQ:068760) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
|A068760||KR Pharmaceuticals||KR Market|
Return vs Industry: A068760 underperformed the KR Pharmaceuticals industry which returned -27.6% over the past year.
Return vs Market: A068760 underperformed the KR Market which returned -15.8% over the past year.
|A068760 Average Weekly Movement||6.3%|
|Pharmaceuticals Industry Average Movement||4.4%|
|Market Average Movement||5.5%|
|10% most volatile stocks in KR Market||10.3%|
|10% least volatile stocks in KR Market||3.2%|
Stable Share Price: A068760 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: A068760's weekly volatility (6%) has been stable over the past year.
About the Company
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies.
Celltrion Pharm Fundamentals Summary
|A068760 fundamental statistics|
Is A068760 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A068760 income statement (TTM)|
|Cost of Revenue||₩193.89b|
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
|Earnings per share (EPS)||692.73|
|Net Profit Margin||9.47%|
How did A068760 perform over the long term?See historical performance and comparison
Is Celltrion Pharm undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate A068760's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A068760's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: A068760 is poor value based on its PE Ratio (112x) compared to the KR Pharmaceuticals industry average (25.3x).
PE vs Market: A068760 is poor value based on its PE Ratio (112x) compared to the KR market (14.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate A068760's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: A068760 is overvalued based on its PB Ratio (9.6x) compared to the KR Pharmaceuticals industry average (1.7x).
How is Celltrion Pharm forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Celltrion Pharm has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Celltrion Pharm performed over the past 5 years?
Past Performance Score3/6
Past Performance Score 3/6
Growing Profit Margin
Earnings vs Industry
Last years earnings growth
Earnings and Revenue History
Quality Earnings: A068760 has high quality earnings.
Growing Profit Margin: A068760's current net profit margins (9.5%) are higher than last year (5.9%).
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if A068760's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare A068760's past year earnings growth to its 5-year average.
Earnings vs Industry: A068760 earnings growth over the past year (146.8%) exceeded the Pharmaceuticals industry -15.5%.
Return on Equity
High ROE: A068760's Return on Equity (8.6%) is considered low.
How is Celltrion Pharm's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: A068760's short term assets (₩257.2B) exceed its short term liabilities (₩208.3B).
Long Term Liabilities: A068760's short term assets (₩257.2B) exceed its long term liabilities (₩61.9B).
Debt to Equity History and Analysis
Debt Level: A068760's net debt to equity ratio (51.5%) is considered high.
Reducing Debt: A068760's debt to equity ratio has reduced from 67.7% to 63% over the past 5 years.
Debt Coverage: A068760's debt is not well covered by operating cash flow (14.9%).
Interest Coverage: A068760's interest payments on its debt are well covered by EBIT (6.7x coverage).
What is Celltrion Pharm current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate A068760's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate A068760's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if A068760's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if A068760's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as A068760 has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Jung-su Seo is Chief Executive Officer and Internal Director of Celltrion Pharm, Inc.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Celltrion Pharm, Inc.'s employee growth, exchange listings and data sources
- Name: Celltrion Pharm, Inc.
- Ticker: A068760
- Exchange: KOSDAQ
- Founded: 1976
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₩2.829t
- Shares outstanding: 37.57m
- Website: https://www.celltrionph.com
- Celltrion Pharm, Inc.
- 82, 2sandan-ro
- South Korea
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/17 00:00|
|End of Day Share Price||2022/05/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.